Renerve Limited · ASX:RNV
Renerve — H1 FY2026 Earnings Presentation
14 slides from Renerve's earnings presentation, Mar 17, 2026
Slide 1: Transforming Nerve Repair Through Science
For personal use only ASX:RNV Transforming Nerve Repair Through Science ReNerve Company presentation | Shareholder half year update webinar March 2026
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd Disclaimer: No representation or warranty, express or implied, is made by the Company that (Company) to provide general information about the Company. The information in this the material
Slide 3: Executive Summary
Executive Summary Summary For personal use only Development of Novel Expanding Strong Sales & Nerve Repair & Product Portfolio Distribution Presence Regeneration Products ReNerve is developing a comprehensive 3 product ranges in the US market ReNerve has established logistics, portfolio of products
Slide 4: Board and Management
Board and Management Leadership Team For personal use only Dr Julian Dr David Maja Dr Paul Dr Alex Chick Rhodes McGuire Savage Adamides MD FRACS CEO & Managing CSO & Director Independent Chair Independent Non- Chief Medical Director executive Director Officer (CMO) New board members join ReNerve app
Slide 5: Half year Summary highlights
Executive Half year Summary highlights For personal use only ReNerve quarterly sales '23 to ‘25 (AUD$) Revenue up 60.2% $120,000 Revenue for the half of $163,719, $100,000 up 60.2% from the corresponding period $80,000 $60,000 $40,000 Cash of $4.18M $20,000 With an additional $0.6m to $0 received in
Slide 6: NervAlign approved for use in US DoD & VA healthcare systems
Executive Half year Summary highlights For personal use only NervAlign® approved for use in US Department of Defense (DoD) & Veterans Affairs (VA) healthcare systems • NervAlign® Nerve Cuff approved for use in DoD and VA hospitals • Initial order and reorder received from the DoD and VA network • Fu
Slide 7: Regulatory & development milestones across the NervAlign range
Executive Half year Summary highlights For personal use only Regulatory & development milestones across the NervAlign® range • Additional regulatory approvals for NervAlign® Nerve Cuff in Hong Kong & Malaysia • Further progress in India for the NervAlign® Nerve Cuff approval • Key development milest
Slide 8: EmpliQ tissue product range launched
Executive Half year Summary highlights For personal use only EmpliQ tissue product range launched • First sales of the EmpliQ human tissue products announced • First sales of amniotic tissue range announced • Highlights the importance of ReNerve’s strategic partnership with Berkeley Biologics LLC •
Slide 9: Catalysts Summary CY26
Executive Catalysts Summary CY26 For personal use only Continued focus on sales expansion with first direct sales reps now full-time Approval for the NervAlign® Nerve Cuff in India, a major market opportunity European approval submission, utilising the data from the 'Align' study Approval across add
Slide 10: Company Portfolio
Company Portfolio Product Product Commercial On Market R&D Development Development For personal use only Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental ReNerve Company presentation | March 2026 10
Slide 11: Target Markets
Target 2031 Market USD$6.0Bn USD$6.19Bn For personal use only The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. Our Target Markets Global Nerve Repair Biomaterial Market Dermal and Amniotic Tissue 2025 S
Slide 12: Value drivers for the next 12 months
Empliq products ranges now Continue to expand into Ex- Value drivers for in the US market US markets For personal use only the next 12 months ● Complements the nerve products sales ● ● Establishing partners Ex-USA Pending approval in several ● Anticipating faster sales growth countries in 2026 throu
Slide 13: Investment Highlights
Investment Highlights For personal use only In Market Products Immediate Market Need Growing Market Nerve Cuff transitioned from R&D to Products promote nerve injury recovery and Nerve repair biomaterials and related markets commercial sales with 3 product lines in wound repair leading to faster pat
Slide 14: Contact Us
ReNerve Company presentation | March 2026 Contact Us For personal use only ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia